The International Society of Aesthetic Plastic Surgery Releases Statistics on Cosmetic Procedures Worldwide

NEW YORK, July 28, 2014 /PRNewswire/ — More than 23 million cosmetic surgical and nonsurgical procedures were performed worldwide in 2013, according to statistics released today by the International Society of Aesthetic Plastic Surgery (ISAPS), the leading international society for aesthetic plastic surgery with more than 2,700 board-certified aesthetic plastic surgeon members in 95 countries. For the first time, Brazil edges out the United States in terms of the number of surgical procedures performed, and Botulinum Toxin takes the number one position for number of overall cosmetic procedures performed.

Logo – http://photos.prnewswire.com/prnh/20140725/130376

For the full report of ISAPS statistics along with a press release and a Quick Facts reference guide, click here.

As ISAPS prepares to host its 22nd Biennial Congress in Rio de Janeiro, Brazil in September, this new data will spark debate among the surgeons gathering from 75 countries to share new techniques and discuss cutting-edge information about this expanding field.

“Since our last survey was conducted, we have improved our strategy for gathering data based on statistically sound samples,” noted Carlos Uebel, MD, ISAPS president. “This has been an effort on the part of our society to further enhance our survey methodology and make it more comprehensive,” he continued.

The countries that performed the most cosmetic surgical and nonsurgical procedures in 2013 include:

  • United States – 3,996,631 — (17%)
  • Brazil– 2,141,257 — (9.1%)
  • Mexico – 884,353 — (3.8%)
  • Germany – 654,115 — (2.8%)
  • Spain – 447,177 — (1.9%)

The leading cosmetic surgical procedures performed in 2013 were:

  • Breast Augmentation — (1,773,584)
  • Liposuction (1,614,031)
  • Blepharoplasty (1,379,263)
  • Lipostructure including lipofilling and stem-enhanced lipofilling (1,053,890)
  • Rhinoplasty (954,423)

The leading nonsurgical procedures performed were:

  • Botulinum Toxin (5,145,189)
  • Fillers and Resorbables (3,089,686)
  • Laser Hair Removal (1,440,252)
  • Non-Invasive Facial Rejuvenation (1,307,300)
  • Chemical Peel, CO2 resurfacing, dermabrasion (773,442)

Women had more than 20 million cosmetic procedures; 87.2% of the total. The surgical procedures performed most frequently on women in 2013 were:

  • Breast Augmentation
  • Liposuction
  • Blepharoplasty
  • Lipostructure
  • Breast Lift

Men had more than 3 million cosmetic procedures; 12.8% of the total. The surgical procedures performed the most frequently on men in 2013 were:

  • Rhinoplasty
  • Breast Reduction for Gynecomastia
  • Blepharoplasty
  • Liposuction
  • Otoplasty

ISAPS’ latest statistics indicate that cosmetic surgery is on the rise on a global scale. Rankings are based solely on those countries from which a sufficient survey response was received and data were considered to be representative.

Outlook for Hepatitis Patients Set to Improve with Development of Accessible Treatments

PHILADELPHIA, July 28, 2014 /PRNewswire/ — The Intellectual Property and Science Business of Thomson Reuters, the world’s leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead’s Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment $1,000 per pill.

Hepatitis is an inflammation of the liver and there are five main hepatitis viruses, referred to as types A, B, C, D and E — plus types X and G. The five main types are of the greatest concern because of the burden of illness and death they cause and the potential for epidemic outbreaks. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer, killing close to 1.4 million every year according to the World Health Organization (WHO).

In late 2013, Gilead dramatically changed the hepatitis C treatment landscape with the launch of Sovaldi, an effective cure for many when used in combination with ribavirin. However, the high cost of the treatment keeps it out of reach for the majority of the estimated 130-150 million individuals suffering from the disease.

To raise additional awareness for World Hepatitis Day, Life Sciences Connect analysts complied Sovaldi-Innovative, Cost Effective, Unaffordable, utilizing Cortellis™Competitive Intelligence, the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content, to evaluate the current outlook of therapies in the pipeline. The analysis revealed several alternative treatments in various stages of development. This high activity is expected to create competition that will lessen costs of treatment, making it more affordable and accessible to patients.

The following were among the key treatments found in different stages of development:

Developer

Drug & Mechanism of Action

Indications Under Development

Roche

mericitabine

a nucleoside analog NS5B
polymerase inhibitor
(similar to Sovaldi)

Phase II for Hepatitis

Bristol Myers-Squibb

orally available combination
therapies based on the NS5A
inhibitor daclatasvir, the NS3
protease inhibitor asunaprevir and
the non-nucleoside inhibitor of
HCV NS5B

Phase III

Potential launch in 2015

Abbvie

dasabuvir

(non-nucleoside NS5B
polymerase inhibitor)

veruprevir (HCV NS3/4A protease
inhibitor) and ombitasvir (NS5A
inhibitor), boosted by ritonavir
(+/-ribavirin)

Expected launch Q1 2015

The analysis also includes an infographic illustrating significant shifts in the Hepatitis drug market.

“We conducted this study in recognition of World Hepatitis Day to help raise awareness around this potentially devastating disease and spotlight some drugs in development that may help eradicate it,” said Jon Brett-Harris, managing director of Thomson Reuters IP & Science. “One of the largest barriers in treating hepatitis is accessibility, therefore it is critical to identify the key drugs in development that may help make treatment more attainable.”

Learn more about Cortellis Competitive Intelligence and visit Life Sciences Connect to view the full analysis and other insights into the latest trends in Life Sciences.

ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe

— Trial court awards permanent injunction, damages and costs against APEX

MUNICH, July 28, 2014 /PRNewswire/ — ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks. The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany.

The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013. The court rejected APEX’s request to stay the injunction and its challenge to the validity of ResMed’s patent. The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.

ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014. The additional accused products are:

  • The APEX iCH and XT Fit CPAP devices
  • The APEX WiZARD 210 and WiZARD 220 masks

“ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort,” said David Pendarvis, ResMed global general counsel and chief administrative officer. “We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists.”

About ResMed:

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:
For News Media

For Investors

Gretchen Griswold

Agnes Lee

Director, Global Corporate Communications

Senior Director, Investor Relations

O: +1-858-836-6789

O: +1-858-836-5971

news@resmed.com

investorrelations@resmed.com